2022
1432. Exploring Cell Wall Targets to Overcome Mycobacterium tuberculosis (Mtb): Ceftriaxone (CRO) Inhibits LdtMt2, a Major Peptidoglycan (PG) Synthase
Nguyen D, Redmond S, Dousa K, Bethel C, Taracila M, Li Q, Kurz S, Pavelka M, Papp-Wallace K, Holland S, Kreiswirth B, Boom H, Bonomo R. 1432. Exploring Cell Wall Targets to Overcome Mycobacterium tuberculosis (Mtb): Ceftriaxone (CRO) Inhibits LdtMt2, a Major Peptidoglycan (PG) Synthase. Open Forum Infectious Diseases 2022, 9: ofac492.1261. PMCID: PMC9752925, DOI: 10.1093/ofid/ofac492.1261.Peer-Reviewed Original ResearchDrug-resistant tuberculosisB-lactamaseMTB isolatesDifficult-to-treat infectionsB-lactamase inhibitorsFractional inhibitory concentration indexMultidrug-resistant mycobacteriaIn vitro susceptibilityCystic Fibrosis FoundationBroth microdilution methodPG synthasesElectrospray ionization-mass spectrometryCeftriaxone MICsDR-TBSusceptibility testingImipenemMeropenemTB guidelinesCeftriaxoneB-lactamTreatment strategiesClinical studiesLowered MICClavulanateMicrodilution method
2017
Drug Resistance Assays for Mycobacterium tuberculosis
Kurz S, Salfinger M. Drug Resistance Assays for Mycobacterium tuberculosis. 2017, 1359-1365. DOI: 10.1007/978-3-319-47266-9_33.Peer-Reviewed Original ResearchDetection of drug resistanceEpidemic of drug-resistant tuberculosisAgar proportion methodAntimicrobial susceptibility testingDrug-resistant tuberculosisDrug resistance assaysDetection of patientsDrug-resistant Mycobacterium tuberculosis strainsMycobacterium tuberculosis strainsMinimal inhibitory concentrationPharmacodynamic correlationsSusceptibility testingDrug resistanceLiquid medium systemsEffective treatmentTuberculosis strainsScreening testProportion methodGenotyping methodsResistance assaysBacteriological methodsInhibitory concentrationMycobacterium tuberculosisTuberculosisPatients
2016
Drug-Resistant Tuberculosis Challenges and Progress
Kurz S, Furin J, Bark C. Drug-Resistant Tuberculosis Challenges and Progress. Infectious Disease Clinics Of North America 2016, 30: 509-522. PMID: 27208770, PMCID: PMC4876017, DOI: 10.1016/j.idc.2016.02.010.Peer-Reviewed Original ResearchConceptsEmergence of drug-resistant tuberculosisCombination drug regimensEmergence of drug-resistant strainsDrug-resistant tuberculosisDrug-resistant strainsSpontaneous chromosomal mutationsCase of Mycobacterium tuberculosisDrug regimensClinical developmentAntimicrobial resistanceSupervised therapyChromosomal mutationsTB controlResistance mechanismsRegimensTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply